![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
NGM282, a Novel Variant of FGF19, Significantly Reduces Hepatic Steatosis and Key Biomarkers of NASH: Results of a Phase 2, Multicenter, Randomized, Double-Blinded, Placebo Controlled Trial in Biopsy-Confirmed NASH Patients
|
|
|
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Stephen A.Harrison, Manal F.Abdelmalek, James F.Trotter,
Angelo H.Paredes, Hays L.Arnold, MarceloKugelmas, Mustafa R.Bashir, LeiLing, Stephen J.Rossi, Alex M.DePaoli, Mary E.Rinella, Rohit Loomba
![CROI1](../images/042217/042217-14/CROI1.gif)
![CROI2](../images/042217/042217-14/CROI2.gif)
![CROI3](../images/042217/042217-14/CROI3.gif)
![CROI4](../images/042217/042217-14/CROI4.gif)
![CROI5](../images/042217/042217-14/CROI5.gif)
![CROI6](../images/042217/042217-14/CROI6.gif)
![CROI7](../images/042217/042217-14/CROI7.gif)
![CROI8](../images/042217/042217-14/CROI8.gif)
![CROI9](../images/042217/042217-14/CROI9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|